Carlo Toniatti – CSO, IRBM

Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key emerging trends within the cancer field and assesses AI’s potential as a truly transformative asset within the drug developer’s toolbox.  
It is now crystal clear that a one-size-fits-all approach is not the way to go in oncology
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report